Fintel reports that on May 4, 2026, Jefferies initiated coverage of COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial ...

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways may be the first to benefit from an accelerated approval process.

This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ:CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...